Company Announcements

Beckley Psytech announces partnership with Empatica in latest step of digital strategy, designed to ...

Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials. New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools i... Read More

Company Announcements

Beckley Psytech to present at 32nd Annual Oppenheimer Healthcare Conference

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the ... Read More

Company Announcements

Beckley Psytech announces dosing of first healthy volunteers in Phase 1 clinical trial assessing saf...

Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT. BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices.... Read More

Company Announcements

Beckley Psytech bolsters pipeline of next-generation psychedelic medicines with research collaborati...

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckley Psytech’s world class management and R&D team

Company Announcements

Beckley Psytech publishes peer-reviewed paper on 5-MeO-DMT in Journal of Psychopharmacology

Literature review highlights need for further clinical exploration of 5-MeO-DMT

Company Announcements

Beckley Psytech to attend and present at 8th Annual LSX World Congress 2022

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the ... Read More

Company Announcements

Beckley Psytech to present at H.C. Wainwright 2nd Annual Psychedelics Conference and Stifel 2nd An...

Company Announcements

Beckley Psytech announces first cohort of psychotherapists have begun training for treatment resista...

Initiation of training represents key step to incorporate psychedelic-assisted psychotherapy to deliver potentially clinically meaningful improvements

Company Announcements

Beckley Psytech to attend 11th Annual LifeSci Partners Virtual Corporate Access Event

CEO to participate in a panel discussion on the topic of “Psychedelics: More Than Just a Trip” – January 5, 2022 at 10:00 am ET / 3:00 pm GMT

Company Announcements

Beckley Psytech announces first cohort dosed in Phase 1 clinical trial assessing safety and tolerabi...

Press release